Shanghai Junshi Biosciences Co., Ltd. (SHJBF)
USD 1.97
(51.54%)
USD 1.97
(51.54%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.98 Billion CNY | 58.49% |
| 2022 | -4.79 Billion CNY | -66.64% |
| 2021 | -2.87 Billion CNY | -13.5% |
| 2020 | -2.53 Billion CNY | -621.87% |
| 2019 | -351.06 Million CNY | 83.99% |
| 2018 | -2.19 Billion CNY | -723.58% |
| 2017 | -266.29 Million CNY | -139.07% |
| 2016 | -111.38 Million CNY | 69.39% |
| 2015 | -363.92 Million CNY | -1121.56% |
| 2014 | -29.79 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 39.37 Million USD | 294.37% |
| 2024 Q2 | -142.03 Million CNY | 90.69% |
| 2024 Q1 | -210.99 Million USD | 23.69% |
| 2023 Q4 | -282.18 Million USD | 22.35% |
| 2023 FY | -1.98 Billion CNY | 58.49% |
| 2023 Q1 | -527.2 Million USD | 89.0% |
| 2023 Q2 | -3.44 Billion CNY | -553.81% |
| 2023 Q3 | -363.42 Million USD | 89.46% |
| 2022 Q1 | -3.62 Billion USD | -26.18% |
| 2022 Q3 | -228.63 Million USD | 90.05% |
| 2022 Q4 | -4.79 Billion CNY | -1996.47% |
| 2022 FY | -4.79 Billion CNY | -66.64% |
| 2022 Q2 | -2.29 Billion CNY | 36.66% |
| 2021 Q2 | -3.41 Billion CNY | -42.03% |
| 2021 FY | -2.87 Billion CNY | -13.5% |
| 2021 Q4 | -2.87 Billion CNY | -13.83% |
| 2021 Q3 | -2.52 Billion USD | 26.05% |
| 2021 Q1 | -2.4 Billion USD | 5.07% |
| 2020 Q4 | -2.53 Billion CNY | 21.82% |
| 2020 FY | -2.53 Billion CNY | -621.87% |
| 2020 Q3 | -3.24 Billion CNY | -805.36% |
| 2020 Q2 | 459.56 Million CNY | -62.36% |
| 2020 Q1 | 1.22 Billion CNY | 447.77% |
| 2019 Q4 | -351.06 Million CNY | 0.0% |
| 2019 Q1 | -1.72 Billion CNY | 21.53% |
| 2019 FY | -351.06 Million CNY | 83.99% |
| 2019 Q2 | -1.47 Billion CNY | 14.3% |
| 2018 Q2 | -162.23 Million CNY | -139.21% |
| 2018 Q1 | 413.73 Million CNY | 255.36% |
| 2018 FY | -2.19 Billion CNY | -723.58% |
| 2018 Q4 | -2.19 Billion CNY | -7806.17% |
| 2018 Q3 | 28.46 Million CNY | 117.54% |
| 2017 Q2 | -231.09 Million CNY | 0.0% |
| 2017 Q4 | -266.29 Million CNY | 0.0% |
| 2017 FY | -266.29 Million CNY | -139.07% |
| 2017 Q1 | -231.09 Million CNY | -107.47% |
| 2016 FY | -111.38 Million CNY | 69.39% |
| 2016 Q2 | -180.07 Million CNY | 0.0% |
| 2016 Q1 | -180.07 Million CNY | 50.52% |
| 2016 Q4 | -111.38 Million CNY | 0.0% |
| 2016 Q3 | -111.38 Million CNY | 38.14% |
| 2015 Q1 | -10.48 Million CNY | 64.82% |
| 2015 FY | -363.92 Million CNY | -1121.56% |
| 2015 Q3 | -363.92 Million CNY | -3372.55% |
| 2015 Q4 | -363.92 Million CNY | 0.0% |
| 2015 Q2 | -10.48 Million CNY | 0.0% |
| 2014 Q4 | -29.79 Million CNY | 0.0% |
| 2014 FY | -29.79 Million CNY | 0.0% |
| 2014 Q3 | -29.79 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 20.27 Million USD | 9912.463% |
| Skye Bioscience, Inc. | -5.72 Million USD | -34674.335% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -31457.894% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -796941.503% |
| Qrons Inc. | 351.42 Thousand USD | 566241.759% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 44589.493% |
| CSL Limited | 10.52 Billion USD | 118.902% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 4749.3% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 35323.879% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 313336.519% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 4680.686% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -9748895.492% |
| Rebus Holdings, Inc. | 305 Thousand USD | 652419.672% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -151875854.198% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 319780.284% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 10014571.234% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 12721.804% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 48413.827% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 495205.127% |
| SQZ Biotechnologies Company | -36.23 Million USD | -5390.3% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 88831.858% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 214682.08% |
| Mesoblast Limited | 55.85 Million USD | 3661.828% |
| Marizyme, Inc. | 18.56 Million USD | 10814.481% |
| Genus plc | 190.6 Million USD | 1143.848% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 89085.89% |
| Pharming Group N.V. | 109.8 Million USD | 1911.933% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 231381.118% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 164001.035% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 292684.559% |
| ContraFect Corporation | -6.02 Million USD | -32916.512% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 1477810.767% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 172293.618% |
| IMV Inc. | 7.67 Million USD | 26037.938% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 36261.625% |
| MultiCell Technologies, Inc. | 90.04 USD | 2209656919.191% |
| ONE Bio Corp. | 9.04 Million USD | 22108.488% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -270967.389% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 15468.26% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 145539.852% |
| Q BioMed Inc. | 4.06 Million USD | 49104.214% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 6611.668% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 197534.098% |
| Biomind Labs Inc. | 711.4 Thousand USD | 279769.582% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 3386.069% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 99609.001% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 15635.556% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 553205.279% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 1423217.364% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 90453.868% |
| GB Sciences, Inc. | 1.74 Million USD | 113964.636% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -1082438.033% |
| HST Global, Inc. | 96.79 Thousand USD | 2055594.716% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 964896.792% |
| Halberd Corporation | 144.72 Thousand USD | 1374865.929% |
| Enzolytics Inc. | 981.65 Thousand USD | 202775.377% |
| Agentix Corp. | 37.63 Thousand USD | 5287163.857% |
| Resverlogix Corp. | 6.45 Million USD | 30941.342% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -295488.696% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 1.936% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -4132.058% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 28237.221% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 73553.592% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -22406.729% |
| AVAX Technologies, Inc. | -5.9 Million USD | -33603.29% |
| Zenith Capital Corp. | 10.06 Thousand USD | 19769326.948% |
| Genscript Biotech Corporation | -1.06 Billion USD | -87.46% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 992743.39% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 83484.185% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 1209501.917% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -10861211.279% |
| Kadimastem Ltd | -253.1 Thousand USD | -785976.364% |
| Helix BioMedix, Inc. | -2.57 Million USD | -77314.406% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 988689.047% |
| LadRx Corporation | -2.03 Million USD | -97597.289% |
| Cell Source, Inc. | 9.23 Million USD | 21650.923% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 313336.519% |
| NovAccess Global Inc. | 2.17 Million USD | 91429.216% |
| Affymax, Inc. | -5.59 Million USD | -35447.168% |
| Itoco Inc. | 228.3 Thousand USD | 871554.852% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 1463141.128% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 40236.675% |
| Mobile Lads Corp. | 484.23 Thousand USD | 410972.268% |
| CytoDyn Inc. | 20.26 Million USD | 9919.243% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -307507627.975% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -21466257.514% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 25918.511% |
| SYBLEU INC | 473.71 Thousand USD | 420094.976% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 44739.111% |
| International Stem Cell Corporation | 2.59 Million USD | 76917.568% |
| Bioxytran, Inc. | 1.89 Million USD | 104874.361% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 3187857.358% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 91327.246% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 58037.536% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 23361.721% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 257614.493% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -159066.0% |
| Neutra Corp. | 52.18 Thousand USD | 3812495.807% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -79834.713% |
| PureTech Health plc | -167.19 Million USD | -1089.959% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -812276.484% |
| IXICO plc | -4.44 Million USD | -44664.002% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 15150.874% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 3727.236% |
| CSL Limited | 10.52 Billion USD | 118.902% |
| Cellectis S.A. | -43.81 Million USD | -4440.452% |